A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram
- PMID: 17435554
- PMCID: PMC1877014
- DOI: 10.1097/01.sla.0000250439.86020.85
A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram
Abstract
Objective: To compare sentinel lymph node (SLN)-positive breast cancer patients who had completion axillary dissection (ALND) with those who did not, with particular attention to clinicopathologic features, nomogram scores, rates of axillary local recurrence (LR), and changes in treatment pattern over time.
Background: While conventional treatment of SLN-positive patients is to perform ALND, there may be a low-risk subgroup of SLN-positive patients in whom ALND is not required. A multivariate nomogram that predicts the likelihood of residual axillary disease may assist in identifying this group.
Methods: Among 1960 consecutive SLN-positive patients (1997-2004), 1673 (85%) had ALND ("SLN+/ALND") and 287 (15%) did not ("SLN+/no ALND"). We compare in detail the clinicopathologic features, nomogram scores, and rates of axillary LR between groups.
Results: Compared with the SLN+/ALND group, patients with SLN+/no ALND were older, had more favorable tumors, were more likely to have breast conservation, had a lower median predicted risk of residual axillary node metastases (9% vs. 37%, P < 0.001), and had a marginally higher rate of axillary LR (2% vs. 0.4%, P = 0.004) at 23 to 30 months' follow-up; half of all axillary LR in SLN+/no ALND patients were coincident with other local or distant sites. For patients in whom intraoperative frozen section was either negative or not done, the rate of completion ALND declined from 79% in 1997 to 62% in 2003 to 2004 but varied widely by surgeon, ranging from 37% to 100%. For 10 of 10 evaluable surgeons, the median nomogram scores in the SLN+/no ALND group were <or=10.5.
Conclusions: SLN+/no ALND breast cancer patients, a selected group with relatively favorable disease characteristics, had a 9% predicted likelihood of residual axillary disease by nomogram but an observed axillary LR of 2%. A gradual and significant decline over time in the rate of completion ALND is associated with, but not entirely explained by, the institution of a predictive nomogram. It is reasonable to omit ALND for a low-risk subset of SLN-positive patients.
Figures




Similar articles
-
The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.Ann Surg. 2004 Sep;240(3):462-8; discussion 468-71. doi: 10.1097/01.sla.0000137130.23530.19. Ann Surg. 2004. PMID: 15319717 Free PMC article.
-
Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.J Invest Surg. 2019 Jan;32(1):48-54. doi: 10.1080/08941939.2017.1375051. Epub 2017 Sep 25. J Invest Surg. 2019. PMID: 28945489
-
Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.Breast Cancer Res Treat. 2019 Jan;173(2):343-352. doi: 10.1007/s10549-018-5004-7. Epub 2018 Oct 20. Breast Cancer Res Treat. 2019. PMID: 30343457 Clinical Trial.
-
Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.BMC Surg. 2023 Jul 26;23(1):209. doi: 10.1186/s12893-023-02101-8. BMC Surg. 2023. PMID: 37495945 Free PMC article.
-
[Is axillary lymph node dissection always necessary in breast cancer patients with a positive sentinel node?].J Chir (Paris). 2007 Nov-Dec;144(6):492-501. doi: 10.1016/s0021-7697(07)79774-0. J Chir (Paris). 2007. PMID: 18235360 Review. French.
Cited by
-
Current status of sentinel lymph-node biopsy in patients with breast cancer.Eur J Nucl Med Mol Imaging. 2011 Mar;38(3):562-75. doi: 10.1007/s00259-010-1577-z. Epub 2010 Aug 11. Eur J Nucl Med Mol Imaging. 2011. PMID: 20700739 Review.
-
Elaboration of a nomogram to predict nonsentinel node status in breast cancer patients with positive sentinel node, intraoperatively assessed with one step nucleic amplification: Retrospective and validation phase.J Exp Clin Cancer Res. 2016 Dec 8;35(1):193. doi: 10.1186/s13046-016-0460-6. J Exp Clin Cancer Res. 2016. PMID: 27931238 Free PMC article.
-
Evolving Trends in Surgical Management of Breast Cancer: An Analysis of 30 Years of Practice Changing Papers.Front Oncol. 2021 Aug 4;11:622621. doi: 10.3389/fonc.2021.622621. eCollection 2021. Front Oncol. 2021. PMID: 34422626 Free PMC article. Review.
-
Nomogram for predicting the risk of central lymph node metastasis in papillary thyroid microcarcinoma: a combination of sonographic findings and clinical factors.Gland Surg. 2024 Jun 30;13(6):1016-1030. doi: 10.21037/gs-24-154. Epub 2024 Jun 19. Gland Surg. 2024. PMID: 39015718 Free PMC article.
-
Predicting non-sentinel lymph node status after positive sentinel biopsy in breast cancer: what model performs the best in a Czech population?Pathol Oncol Res. 2009 Dec;15(4):733-40. doi: 10.1007/s12253-009-9177-6. Epub 2009 May 15. Pathol Oncol Res. 2009. PMID: 19440855
References
-
- Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003;349:546–553. - PubMed
-
- Wilke LG, McCall LM, Posther KE, et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol. 2006;13:491–500. - PubMed
-
- Temple LK, Baron R, Cody HS III, et al. Sensory morbidity after sentinel lymph node biopsy and axillary dissection: a prospective study of 233 women. Ann Surg Oncol. 2002;9:654–662. - PubMed
-
- Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma. Cancer. 2006;106:4–16. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical